In Scotland, bivalent HPV vaccination prevented most cervical high-grade neoplasia in both immunized and unimmunized women.
In clinical trials, the bivalent human papillomavirus (HPV) vaccine has high efficacy in preventing cervical HPV-related neoplasia and its precursors, but HPV immunization's real-world effects are still being evaluated. In 2008, Scotland launched a national HPV immunization program aimed at 12- to 13-year-old girls and including catch-up immunization of girls aged 14 to 18. Population-based surveillance has allowed linkage of vaccine status with cytologic screening results in 20-year-olds, enabling researchers to assess cervical disease status in some 21,000 routinely vaccinated women (born in 1995–1996) compared with 18,000 unvaccinated women (born in 1988–1990; preimmunization).
Rates of cervical intraepithelial neoplasia (CIN) were lower …
Reviewing Authors
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)